Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation (Nasdaq: BRKR) SEC filings page provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q, and other key documents. These filings offer detailed information on Bruker’s financial condition, operating performance, capital structure, and material corporate events.
Bruker’s Form 8-K filings illustrate how the company reports significant developments such as quarterly and interim financial results, material modifications to security holder rights, and securities offerings. For example, Bruker has filed 8-Ks to furnish press releases with results of operations and financial condition for specific quarters, and to describe the issuance and terms of its 6.375% Mandatory Convertible Preferred Stock, Series A. That filing outlines the preferred stock’s dividend rate, liquidation preference, conversion mechanics into common stock, and related restrictions on dividends and share repurchases affecting junior and parity stock.
Through Forms 10-K and 10-Q, users can review segment information for Bruker Scientific Instruments and the Bruker Energy & Supercon Technologies (BEST) division, along with discussions of markets served, risk factors, and management’s analysis of results. These filings also describe how Bruker’s scientific instruments and diagnostic solutions support life science, applied, biopharma, industrial and cleantech research, and semiconductor metrology applications.
On this page, Stock Titan enhances Bruker’s raw SEC filings with AI-powered summaries that explain complex sections in plain language. Users can quickly understand the implications of Bruker’s 10-K and 10-Q reports, preferred stock terms, and other material events, while still having direct access to the original EDGAR documents. Filings related to insider transactions on Form 4 and proxy materials on Schedule 14A can also be monitored to track executive equity activity and governance matters over time.
Bruker Corporation announced a regular income payment for holders of its 6.375% Mandatory Convertible Preferred Stock, Series A. The Board declared a quarterly cash dividend of $3.9844 per share.
The dividend was declared on April 28, 2026 and will be paid on June 1, 2026 to shareholders of record as of May 15, 2026.
Bruker Corp executive Mark Munch exercised stock options and sold shares in a planned transaction. He exercised options for 2,000 shares of common stock at $22.19 per share and then sold 2,000 shares at $39.90 per share on the same date.
After these transactions, he directly owns 128,443 shares of Bruker common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person.
BRKR filing reports an intended sale of 2,000 shares of Common Stock on 04/15/2026 via a stock option exercise for cash. The filing also lists prior reported dispositions by Mark R. Munch: 2,000 shares on 03/13/2026 for $70,880 and 2,000 shares on 02/13/2026 for $73,880.
Bruker Corporation is asking stockholders to vote at its virtual 2026 Annual Meeting on May 21, 2026. Investors will elect three Class II directors (Laura A. Francis, John J. Phillips, and Hermann F. Requardt), approve on an advisory basis 2025 executive pay, and ratify PricewaterhouseCoopers as auditor for 2026.
The company highlights a pay-for-performance program combining salary, annual cash incentives and long‑term equity, with no broad perquisites and a clawback policy. In 2025, revenue reached $3.4365 billion but organic revenue and non‑GAAP margins declined, reducing incentive payouts. The proxy also details board structure, committee roles, director compensation and significant share ownership, including CEO Frank Laukien’s 26.6% stake.
BRUKER CORP director Bernard Thierry has filed a Form 3 as a reporting person for the company’s stock. The filing shows no reported transactions, with all buy, sell, acquire, and dispose counts and share amounts listed as zero in the transaction summary.
Bruker Corporation announced that Falko Busse, Ph.D., an executive officer and President of the Bruker BioSpin Group, will transition his duties on or around May 1, 2026, with his employment ending on October 31, 2026.
Under a mutual separation agreement with Bruker Switzerland AG, Dr. Busse will receive separation benefits, including severance, a pro-rated bonus, and unused vacation payout totaling an amount in Swiss francs approximately equal to $1,020,351, payable on the separation date. Any unvested equity awards held on that date will be forfeited. The agreement also includes customary restrictive covenants and confidentiality, non-solicitation, and non-disparagement obligations.
Bruker Corporation has expanded its Board of Directors to twelve members and appointed Thierry L. Bernard as a Class III director, effective April 1, 2026. He will serve until the 2027 Annual Meeting of Stockholders.
Bernard is currently CEO and Managing Director of QIAGEN N.V., with a previously announced transition plan under which he will step down once a successor is appointed. His background spans senior roles at bioMérieux and other international life-science companies, as well as board leadership at AdvaMedDx and Neogen Corporation. His compensation as a non-employee director will match Bruker’s existing director compensation program, and the company states there are no related-party transactions requiring disclosure. Bruker will later disclose his Board committee assignments.
Bruker Corp — Amendment No. 8 to a Schedule 13G/A was filed reporting that The Vanguard Group beneficially owns 0 shares of Bruker Corp common stock, representing 0% of the class. The filing explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that caused certain Vanguard subsidiaries or business divisions to report ownership separately. The filer states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries/divisions. The form is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
BRUKER CORP executive Mark Munch reported an option exercise and share sale. On March 13, he exercised stock options for 2,000 shares of common stock at $22.19 per share, then sold 2,000 shares of common stock at $35.44 per share.
Following these transactions, he directly held 128,443 shares of common stock. The filing notes that the sale was carried out under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, routine liquidity event rather than an opportunistic trade.